NCT02541604 · OUTCOME

Percentage of Participants Adverse Events, Serious Adverse Events and Adverse Events of Special Interest

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors · Source last updated 2020-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage
Interval / dispersion: Not reported
Time frame: From baseline up to approximately 42 months

Analysis population: Included safety-evaluable population, defined as patients who received any amount of study drug.

Groups in this outcome

Atezolizumab

Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \[mg\]) on Day 1 of each 21-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Atezolizumab	87

Reported measurements

Adverse Events

Values in Percentage · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Atezolizumab	97.7	Not reported	Not reported	Not reported	Not reported

Serious Adverse Events

Values in Percentage · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Atezolizumab	37.9	Not reported	Not reported	Not reported	Not reported

Adverse Events of Special Interest

Values in Percentage · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Atezolizumab	44.8	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
97.7
title
Adverse Events
categories
measurements
group Id
OG000
value
37.9
title
Serious Adverse Events
categories
measurements
group Id
OG000
value
44.8
title
Adverse Events of Special Interest

denoms

counts
group Id
OG000
value
87
units
Participants

groups

description
Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \[mg\]) on Day 1 of each 21-day cycle.
id
OG000
title
Atezolizumab

param Type

NUMBER

population Description

Included safety-evaluable population, defined as patients who received any amount of study drug.

reporting Status

POSTED

time Frame

From baseline up to approximately 42 months

title

Percentage of Participants Adverse Events, Serious Adverse Events and Adverse Events of Special Interest

type

PRIMARY

unit Of Measure

Percentage

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice